Lead Investigator Shares Early Data With Ibrutinib Maintenance in MCL
Reem Karmali, MD, MS, shares early data with ibrutinib maintenance therapy and highlights recent advances and challenges in the treatment of patients with mantle cell lymphoma.
Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma
Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.
Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies
Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.
CAR T Cells Bring Promise to Patients With ALL, DLBCL With Poor Prognosis
Lazaros J. Lekakis, MD, discusses the promise of CAR T cells and some unanswered questions with this rapidly emerging therapy.
Allogeneic HSCT Retains Role in Relapsed Myeloma
Sergio A. Giralt, MD, discusses recent data with allogeneic hematopoietic stem cell therapy and why this long-standing modality remains an integral part of treatment for patients with relapsed myeloma.
Following bb2121, Novel CAR T-Cell Product Shows Potential in Myeloma
Nina Shah, MD, discusses the promise of bb21217 in the complex treatment paradigm of relapsed/refractory multiple myeloma
Landgren Explains Crucial Role of MRD in Myeloma
C. Ola Landgren, MD, PhD, discusses the role of minimal residual disease negativity and the emergence of CAR T-cell therapy in multiple myeloma.
Expert Discusses Ongoing CAR T-Cell Research in Myeloma
Nina Shah, MD, discusses the present and future of chimeric antigen receptor T-cell therapy in myeloma.
Ongoing Efforts Seek to Refine, Expand CAR T-Cell Therapy
Brian Till, MD, discusses the rapidly evolving field of chimeric antigen receptor (CAR) T cells.
CAR T Cells Could Provide Curative Strategies in Myeloma
Deepu Madduri, MD, discusses the role of CAR T-cell therapy and other novel treatment options for patients with relapsed/refractory multiple myeloma.
Goy Discusses Maintenance, CAR T-Cell Therapy in MCL
Andre Goy, MD, shares insight on the new array of treatment options for mantle cell lymphoma and how to properly implement them.
Flinn Highlights CAR T-Cell Developments in Lymphoma
Ian W. Flinn, MD, PhD, discusses the latest developments with CAR T-cell therapies and other recent advances in the field of lymphoma.
2 Clarke Drive Cranbury, NJ 08512